R W Dal Negro1, B R Celli2. 1. Centro Nazionale Studi di Farmacoeconomia e, Farmacoepidemiologia Respiratoria - CESFAR, Verona, Italy. Electronic address: robertodalnegro@gmail.com. 2. Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: bcelli@copdnet.org.
Abstract
Multidimensional scores were proposed for defining COPD outcomes, but without any incorporation of the economic COPD cost to clinical indices. AIM: using mortality as an outcome, the hypothesis that adding total health care cost to the BODE index would better predict mortality in COPD was investigated. METHODS: 275 COPD patients were surveyed. Anthropometrics, lung function, the BODE and the Charlson Comorbidity Index were determined. History of exacerbations, ER visits, hospitalizations and mortality were also determined over the next three years, being their rates graded and added to the BODE index according to a simple algorithm. The novel PRO-BODE index ranged 0-10 points; its relationship to annual total COPD cost and survival was assessed by linear regression analysis. RESULTS: total COD cost showed the highest relationship with survival (r = -0.58), even higher than that of age and of BODE index (r = -0.28 and r = -0.21, respectively). The integrated Pro-BODE score proved proportional to the cost of care and inversely proportional to the length of survival. CONCLUSIONS: Pro-BODE is a novel composite index which helps in predicting in real life the impact of COPD over three years, both in terms of patients' survival and of COPD economic burden.
Multidimensional scores were proposed for defining COPD outcomes, but without any incorporation of the economic COPD cost to clinical indices. AIM: using mortality as an outcome, the hypothesis that adding total health care cost to the BODE index would better predict mortality in COPD was investigated. METHODS: 275 COPD patients were surveyed. Anthropometrics, lung function, the BODE and the Charlson Comorbidity Index were determined. History of exacerbations, ER visits, hospitalizations and mortality were also determined over the next three years, being their rates graded and added to the BODE index according to a simple algorithm. The novel PRO-BODE index ranged 0-10 points; its relationship to annual total COPD cost and survival was assessed by linear regression analysis. RESULTS: total COD cost showed the highest relationship with survival (r = -0.58), even higher than that of age and of BODE index (r = -0.28 and r = -0.21, respectively). The integrated Pro-BODE score proved proportional to the cost of care and inversely proportional to the length of survival. CONCLUSIONS:Pro-BODE is a novel composite index which helps in predicting in real life the impact of COPD over three years, both in terms of patients' survival and of COPD economic burden.
Authors: María Del Carmen Valls Martínez; Alicia Ramírez-Orellana; Mayra Soledad Grasso Journal: Int J Environ Res Public Health Date: 2021-02-26 Impact factor: 3.390
Authors: Roberto W Dal Negro; Mauro Carone; Giuseppina Cuttitta; Luca Gallelli; Massimo Pistolesi; Salvatore Privitera; Piero Ceriana; Pietro Pirina; Bruno Balbi; Carlo Vancheri; Franca M Gallo; Alfredo Chetta; Paola Turco Journal: Multidiscip Respir Med Date: 2021-10-01